Pharmaceutical companies develop, manufacture, and distribute medications. Notable examples include Pfizer, renowned for its extensive vaccine portfolio and Johnson & Johnson, a diversified healthcare conglomerate.

A high profile company that has gained significant attention lately is Novo Nordisk, a leader in diabetes care and obesity treatments. In 2017, its highly popular drug, Ozempic, which has been used by celebrities as a drug to lose weight rapidly, was approved by the FDA.

At the end of 2018, Novo Nordisk’s market cap was $111 billion. At its height in June 2024, the market cap was $640 billion, becoming the 12th most valuable company globally thanks to positive trial data announced in March 2024 for its experimental weight loss pill, amycretin, and strategic acquisitions.

The pharmaceutical industry’s valuation has experienced fluctuations over the past few years. During the COVID-19 pandemic, the sector saw increased valuations due to the urgent demand for vaccines and treatments.

However, in 2023 and 2024, the industry faced underperformance and investor withdrawal due to higher post-pandemic costs and regulatory concerns.

The Health Care Select Sector ETF traded at a 20% discount to the S&P 500, reflecting this valuation gap.

Pharmaceutical Company Valuation Multiples

Out of 77 pharmaceutical companies, the median P/S revenue multiple is 1.4x. The median EBITDA multiple is 8.9x. The median PE ratio is 19.1x.

Pharma companies are included as a subset of life science companies. Comparatively, the median revenue multiple for life science companies is 3.4x, EBITDA multiple is 20.3x and PE ratio is 32.1x.

Biotech companies‘ revenue multiple is even higher at 6.5x.

Looking Ahead for Pharma in 2025

Looking ahead to 2025, several trends are poised to influence pharmaceutical company valuations:

• The development of effective obesity treatments is expected to drive significant market interest. Companies like Novo Nordisk and Eli Lilly are leading this space with drugs such as Wegovy and Ozempic.
• AI is set to revolutionize drug discovery and personalized treatments. Pharmaceutical companies investing in AI-driven solutions may see improved valuations due to increased R&D productivity.
• The political environment, including potential policy changes under new administrations, can impact drug pricing and market access, thereby affecting company valuations. For instance, recent political developments have introduced uncertainties for companies like Novo Nordisk.

2025 presents opportunities for growth driven by innovation in therapeutics and technology integration.

Companies that effectively navigate the evolving regulatory landscape and leverage advancements in AI and drug development are likely to enhance their market positions and valuations.

Download 2024 Data

To download the dataset consisting of ~80 companies in this analysis, enter your email address below to sign-up for the mailing list and the data set will be sent to your email directly. In some cases, it takes a few hours or a day to receive the email with the data set.